18F-FDG PET/CT与循环肿瘤细胞在初治非小细胞肺癌中的临床效用
该回顾性研究纳入309例初治非小细胞肺癌患者,分析18F-FDG PET/CT代谢参数与循环肿瘤细胞(CTCs)在诊断和预后中的价值。18F-FDG PET/CT诊断灵敏度为96.4%,高于CTCs的75.7%;SUVmax与CTCs阳性显著相关,TLG-P、TLG-C和CTCs是PFS的独立预测因素,TLG-C和CTCs是OS的独立预测因素。
要点
- 18F-FDG PET/CT对初治NSCLC诊断灵敏度96.4%,优于CTCs的75.7%。
- SUVmax与CTCs阳性显著相关,CTCs阳性组代谢参数及CYFRA211更高。
- TLG-P、TLG-C和CTCs是PFS独立预测因素,TLG-C和CTCs是OS独立预测因素。
核心结论
- 18F-FDG PET/CT在初治NSCLC诊断中优于CTCs,外周血CTCs水平与肿瘤葡萄糖代谢相关。
- 18F-FDG PET/CT代谢参数与CTCs可分别预测初治NSCLC患者的预后。
研究设计与样本
- 回顾性研究纳入309例初治NSCLC患者,其中腺癌217例、鳞癌92例;男性200例、女性109例,平均年龄61±9岁。
- 采集血样检测CTCs,分析18F-FDG PET/CT代谢参数(SUVmax、MTV-P、MTV-C、TLG-P、TLG-C),并回顾年龄、性别、吸烟、血清肿瘤标志物、肿瘤大小、位置、TNM分期及基因突变。
- 分析无进展生存期(PFS)和总生存期(OS)。
主要发现
- 309例中18F-FDG PET/CT将11例误诊为良性疾病;CTCs阳性234例。
- 18F-FDG PET/CT和CTCs诊断NSCLC的灵敏度分别为96.4%和75.7%。
- CTCs阳性组SUVmax、MTV-P、TLG-P、MTV-C、TLG-C、肿瘤大小及血清CYFRA211水平显著高于阴性组。
- 晚期TNM分期、鳞状细胞癌和EGFR野生型者CTCs阳性率更高。
- 多因素logistic回归显示SUVmax与CTCs阳性显著相关;多因素Cox回归显示TLG-P、TLG-C和CTCs是PFS独立预测因素,TLG-C和CTCs是OS独立预测因素。
关键数值与推荐
- 18F-FDG PET/CT诊断灵敏度96.4%,CTCs诊断灵敏度75.7%。
- CTCs阳性234例(共309例),18F-FDG PET/CT误诊良性11例。
- SUVmax与CTCs阳性显著相关(多因素logistic回归)。
- TLG-P、TLG-C、CTCs为PFS独立预测因素;TLG-C、CTCs为OS独立预测因素(多因素Cox回归)。
临床怎么用
- 初治NSCLC诊断可优先考虑18F-FDG PET/CT,其灵敏度高于CTCs检测。
- CTCs阳性与更高肿瘤葡萄糖代谢负荷相关,可结合SUVmax等代谢参数综合评估。
- TLG-P、TLG-C和CTCs可用于初治NSCLC患者PFS和OS的预后分层。
局限性
- 本研究为回顾性设计。
- 单中心研究,样本来自单一机构。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study retrospectively investigated the clinical utility of 2-deoxy-18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) and circulating tumor cells (CTCs) in the diagnosis and prognosis of treatment-naive patients with non-small-cell lung cancer (NSCLC). METHODS: The blood samples of treatment-naive patients with NSCLC were collected for CTCs detection, and the tumor metabolic parameters of 18F-FDG PET/CT, including maximum standard uptake value (SUVmax), metabolic tumor volume of primary lesion (MTV-P) and combination of primary lesion and metastases (MTV-C), and total lesion glycolysis of primary lesion (TLG-P) and combination of primary lesion and metastases (TLG-C), were analyzed. Age, sex, smoking, serum tumor markers, tumor size, location, TNM stage, and genetic mutations were also reviewed. Moreover, progression-free survival (PFS) and overall survival (OS) of these patients were analyzed. RESULTS: A total of 309 patients with NSCLC (200 men, 109 women; mean age: 61 ± 9 years) were enrolled in this study, including 217 patients with adenocarcinoma and 92 with squamous cell carcinoma. Of the 309 cases, 11 were misdiagnosed with benign diseases by 18F-FDG PET/CT. CTCs positivity was detected in 234 cases. The sensitivity of 18F-FDG PET/CT and CTCs in NSCLC were 96.4% and 75.7%, respectively. SUVmax, MTV-P, TLG-P, MTV-C, TLG-C, tumor size, and serum CYFRA211 levels were significantly higher in CTCs positive group than negative group; and advanced TNM stage, squamous cell carcinoma, and EGFR wild type presented higher CTCs positivity. Multivariate logistic regression analysis revealed that SUVmax was significantly associated with CTCs positivity. Multivariate cox regression analysis showed that TLG-P, TLG-C, and CTCs were independent predictors of PFS in patients with NSCLC, and TLG-C and CTCs were independent predictors of OS. CONCLUSIONS: 18F-FDG PET/CT was superior to CTCs in the diagnosis of treatment-naive patients with NSCLC. The levels of CTCs in the peripheral blood were associated with tumor glucose metabolism in NSCLC. Metabolic parameters of 18F-FDG PET/CT and CTCs could separately predict the outcomes of treatment-naive patients with NSCLC.
引用
- Zhang F, Wu X, Zhu J, et al. 18F-FDG PET/CT and circulating tumor cells in treatment-naive patients with non-small-cell lung cancer. Eur J Nucl Med Mol Imaging. 2021. PMID: 33630146. doi:10.1007/s00259-021-05260-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。